Catalyst calendar
Data as of 2026-08-19 16:00 UTC · tracked universe polled every 15 minutes
Three kinds of date: a PDUFA date (the deadline the FDA sets itself to decide on a drug application), an AdCom (an FDA advisory-committee meeting that reviews it in public), and a readout window (when a trial's results are expected). Dates marked confirmed by the company come from an 8-K or press-release quote; our estimate is a rule-derived window off the trial's registered primary-completion date (see methodology) — never shown the same way. Today: 200 estimated readout windows and 0 disclosed PDUFA/AdCom dates.
Next 7 days
| Date | Ticker | Phase | Event |
|---|---|---|---|
| 2026-09-27 in 6w | $BIIB | Phase 3 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and… NCT04961567 |
| 2026-09-28 in 6w | $INCY | Phase 2 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous… NCT05888844 |
| 2026-09-30 in 6w | $MRTX | Phase 2 | Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS… NCT05609578 |
| 2026-09-30 in 6w | $ARGX | Phase 2 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of… NCT06392386 |
| 2026-09-30 in 6w | $BIIB | Phase 3 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and… NCT04895241 |
| 2026-09-30 in 6w | $BMY | Phase 1 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced… NCT05888831 |
| 2026-10-01 in 6w | $AMGN | Phase 1 | Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity NCT06585462 |
| 2026-10-01 in 6w | $ARGX | Phase 3 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20… NCT04812925 |
| 2026-10-06 in 7w | $BMY | Phase 3 | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in… NCT06003426 |
| 2026-10-07 in 7w | $REGN | Phase 3 | Study to Assess the Long-term Safety of Dupilumab Administered in Participants… NCT02612454 |
| 2026-10-08 in 7w | $AMGN | Phase 1 | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic… NCT06555796 |
| 2026-10-09 in 7w | $PFE | Phase 1 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With… NCT06447662 |
| 2026-10-09 in 7w | $INCY | Phase 3 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants… NCT06958211 |
| 2026-10-09 in 7w | $INCY | Phase 3 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants… NCT06959225 |
| 2026-10-12 in 8w | $REGN | Phase 3 | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and… NCT05133531 |
| 2026-10-12 in 8w | $BMY | Phase 1 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480… NCT05372354 |
| 2026-10-19 in 9w | $INCY | Phase 3 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in… NCT06516965 |
| 2026-10-19 in 9w | $INCY | Phase 3 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in… NCT06516952 |
| 2026-10-19 in 9w | $PFE | Phase 2 | A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In… NCT05995964 |
| 2026-10-19 in 9w | $INCY | Phase 1 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of… NCT07448155 |
| 2026-10-19 in 9w | $BMY | Phase 3 | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165)… NCT05620407 |
| 2026-10-19 in 9w | $BMY | Phase 3 | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With… NCT05617677 |
| 2026-10-20 in 9w | $BIIB | Phase 2 | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve… NCT05531565 |
| 2026-10-22 in 9w | $AMGN | Phase 3 | A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's… NCT06245408 |
| 2026-10-30 in 10w | $MRTX | Phase 2 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation… NCT05853575 |